Navigation Links
Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
Date:10/10/2007

BOULDER, Colo. and MONTREAL, Oct. 10 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced the initiation of a Phase One clinical trial evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Taxotere(R) (docetaxel; Sanofi Aventis) in patients with solid tumors. Taxotere is an approved chemotherapy agent marketed for use in breast, lung, prostate, gastric and head and neck cancer.

In the first portion of the trial, MGCD0103 will be given orally, three times per week for three weeks in combination with Taxotere, which will be administered on Day 1 of each three-week cycle to patients with cancer where treatment with Taxotere is approved or considered standard of care, or patients who have no available standard of care therapeutic options. Key objectives for this portion of the study will be threefold: to evaluate the safety of administering these two agents together; determine the maximum tolerated dose of MGCD0103 when combined with the two fixed doses of Taxotere; and to define optimal dosing for the second portion of the trial. In the second portion of the trial, objectives include further assessment of the safety of the drug combination, quantification of tumor responses and measurement of the pharmacodynamic and pharmacokinetic characteristics. The trial may enroll up to 50 patients at cancer centers in North America. The trial is expected to take 12 to 18 months to complete.

"This is an important step forward in the clinical development of MGCD0103," said Andrew Allen, executive vice president and chief medical officer of Pharmion Corporation. "Cytotoxic chemotherapies such
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  Decision Resources Group finds that the rheumatoid arthritis ... 2013 to over $18.2 billion in 2023 in the ... Germany , Italy , Spain ... Japan . TNF-alpha inhibitors will remain the leading drug ... but growth will be constrained and patient shares will decline due ...
(Date:9/16/2014)... 2014   Evana Automation Specialists , a leading ... test systems, recently received a contract to provide a ... The Evana solution will help error-proof the process of ... as reduce labor. A catheter adapter, ... assembly cell. The robot will pick the adapter, connector ...
(Date:9/16/2014)... , Sept. 16, 2014 The National ... Institute has simultaneously released the NAMCP Medical Technologies ... Diagnostics Dossier Template © , which provide medical ... for either medical devices or diagnostics that accounts ... each of these technology types (instead of having ...
Breaking Medicine Technology:The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2
... Ind., Nov. 3, 2011 Zimmer Holdings, Inc. (NYSE: ... Anterior Cervical Plate System at the 26th North American ... a generous graft window and narrow waist providing clinicians with ... has a low profile (less than 2mm) which clinical literature ...
... PERKASIE, Pa., Nov. 3, 2011 A new company ... customers for implantable medical devices.  US BioDesign, located in ... medical device OEM firms to broaden the company,s breadth ... founders, Tom Molz – CEO and Skott Greenhalgh – ...
Cached Medicine Technology:Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 2Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 3Newly Launched US BioDesign to Provide OEM Development/Manufacturing Services to Medical Device Customers 2
(Date:9/16/2014)... Former Major League Baseball relief pitcher Kent Tekulve ... surgery at Allegheny General Hospital (AGH) on Friday, September ... 16-year baseball career with the Pittsburgh Pirates and now ... Pittsburgh, was discharged home on Friday, September 12, according ... of AGH’s heart transplant program. , “Mr. Tekulve continues ...
(Date:9/16/2014)... Dennis Thompson HealthDay Reporter ... leading to strong heart fitness can delay a man,s onset ... new study suggests. Blood pressure naturally increases as people ... But men with strong cardio-fitness don,t start drifting toward high ... sedentary men usually experience the early signs of high blood ...
(Date:9/16/2014)... -- Illegal drug use among teens in the United States ... Encouragingly, the new study also found that alcohol ... young people between the ages of 12 and 17 also ... 70,000 people aged 12 and older across the United States ... problems among this age group also dropped from 8.9 percent ...
(Date:9/16/2014)... mathematical model that replicates Ebola outbreaks can no longer ... current epidemic, finds research conducted by the University of ... Mathematics Institute, developed a model that incorporated data from ... , The research, titled Epidemiological Dynamics of Ebola Outbreaks ... applying the available data from the ongoing 2014 outbreak ...
(Date:9/16/2014)... make discoveries everyday, but that doesn,t mean the findings ... for example, the neonatal mortality rate is 10 times ... found that applying an inexpensive topical solution of chlorhexidine ... mortality rate by 24 percent, many Indian parents did ... is not that we don,t have solutions to solve ...
Breaking Medicine News(10 mins):Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 2Health News:Former Pittsburgh Pirates Pitcher and Baseball Analyst Kent Tekulve Undergoes Successful Heart Transplant at Allegheny General Hospital 3Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 2Health News:Blood Pressure Seems to Stay Lower Longer in Fitter Men 3Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Ebola outbreak 'out of all proportion' and severity cannot be predicated 2Health News:Pairing social networks with social motives to close the science gap 2Health News:Pairing social networks with social motives to close the science gap 3
... , , , , , ... , AUDIO: Researchers at Washington ... Click here for more information. , ... , , , , , ...
... Underage and heavy drinking on college campuses continue to ... as the University of Missouri, have made strides in ... continually trying to educate students about the risks of ... students who viewed images of beer cans packaged and ...
... stimulation technique administered to both sides of the brain ... in their hands and arms, according to a new ... Center (BIDMC). Described in today,s Online Issue ... that stroke patients who received bihemispheric transcranial direct current ...
... , WEDNESDAY, Nov. 10 (HealthDay News) -- Researchers have pinpointed ... who die quickly from acute myeloid leukemia (AML) from those ... Nov. 11 issue of the New England Journal of ... best candidates for more aggressive initial treatment. The insights might ...
... (Garrison, NY) Organizations that seek to provide health care, food, ... in developing countries often face ethical dilemmas: Are they doing ... a corrupt system and ultimately building its capacity to detain ... in an article coauthored by Nancy Berlinger and Michael Gusmano, ...
... is not much better than a death sentence, given a survival ... victim of the ability to breathe. But researchers at the ... that may serve as a marker for a rapidly progressing form ... tissue in the lungs. More than just signaling which patients ...
Cached Medicine News:Health News:Mutations in single gene predict poor outcomes in adult leukemia 2Health News:Mutations in single gene predict poor outcomes in adult leukemia 3Health News:Mutations in single gene predict poor outcomes in adult leukemia 4Health News:Mutations in single gene predict poor outcomes in adult leukemia 5Health News:Mutations in single gene predict poor outcomes in adult leukemia 6Health News:Team colors on cans change perceptions of alcohol risks, MU study finds 2Health News:Noninvasive brain stimulation helps improve motor function in stroke patients 2Health News:Noninvasive brain stimulation helps improve motor function in stroke patients 3Health News:Gene Mutations Seem to Make a Leukemia More Deadly 2Health News:Gene Mutations Seem to Make a Leukemia More Deadly 3Health News:Researchers see ethical dilemmas of providing care in drug detention centers 2Health News:New indicator found for rapidly progressing form of deadly lung disease 2
... onsite test! QuickScreen multi-panel dip cards offer ... your choice of any conceivable combination of ... flexibility for your drug testing program. Just ... the built-in timer tells you when to ...
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... are highly accurate in detecting the presence of ... by GC/MS testing. This assay provides a preliminary ... as GC/MS) must be used in order to ... applied to any drug of abuse test result, ...
Medicine Products: